{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T18:40:43Z","timestamp":1783968043274,"version":"3.55.0"},"reference-count":83,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009010","name":"Novartis Pharmaceuticals UK Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014653","name":"NIHR Manchester Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000770","name":"The University of Manchester","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000770","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/N025989\/1"],"award-info":[{"award-number":["MR\/N025989\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021672","name":"NIHR Leicester Clinical Research Facility","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021672","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000836","name":"University of Liverpool","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000836","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"F Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004755","name":"EMD Serono","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004755","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.autrev.2022.103184","type":"journal-article","created":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T19:50:54Z","timestamp":1661629854000},"page":"103184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Predicting progression from undifferentiated connective tissue disease to definite connective tissue disease: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6201-7391","authenticated-orcid":false,"given":"Sarah","family":"Dyball","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia","family":"Rodziewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Mendoza-Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3047-500X","authenticated-orcid":false,"given":"Ian N.","family":"Bruce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.autrev.2022.103184_bb0005","first-page":"615","article-title":"Undifferentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classification criteria","volume":"17","author":"Mosca","year":"1999","journal-title":"Clin. Exp. Rheumatol."},{"issue":"7","key":"10.1016\/j.autrev.2022.103184_bb0010","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1164\/rccm.200702-220OC","article-title":"Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?","volume":"176","author":"Kinder","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"5","key":"10.1016\/j.autrev.2022.103184_bb0015","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/acr.23894","article-title":"Incomplete systemic lupus erythematosus: what remains after application of American college of rheumatology and systemic lupus international collaborating clinics criteria?","volume":"72","author":"Lambers","year":"2020","journal-title":"Arthritis Care Res."},{"issue":"3","key":"10.1016\/j.autrev.2022.103184_bb0020","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/ard.2010.136929","article-title":"Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi consensus study from EULAR scleroderma trials and research group","volume":"70","author":"Avouac","year":"2011","journal-title":"Ann. Rheum. Dis."},{"issue":"12","key":"10.1016\/j.autrev.2022.103184_bb0025","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1002\/art.24038","article-title":"Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud\u2019s phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis","volume":"58","author":"Koenig","year":"2008","journal-title":"Arthritis Rheum."},{"issue":"12","key":"10.1016\/j.autrev.2022.103184_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(21)00244-7","article-title":"Progression of patients with Raynaud\u2019s phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS)","volume":"3","author":"Bellando-Randone","year":"2021","journal-title":"Lancet Rheumatol."},{"issue":"16","key":"10.1016\/j.autrev.2022.103184_bb0035","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1056\/NEJMoa021933","article-title":"Development of autoantibodies before the clinical onset of systemic lupus erythematosus","volume":"349","author":"Arbuckle","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.autrev.2022.103184_bb0040","doi-asserted-by":"crossref","first-page":"R174","DOI":"10.1186\/ar3927","article-title":"Autoantibody profiling to follow evolution of lupus syndromes","volume":"14","author":"Olsen","year":"2012","journal-title":"Arthritis. Res. Ther."},{"key":"10.1016\/j.autrev.2022.103184_bb0045","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.autrev.2022.103184_bb0050","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.autrev.2022.103184_bb0055","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan \u2014 a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst. Rev."},{"key":"10.1016\/j.autrev.2022.103184_bb0060","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.3","article-title":"Chapter 6: choosing effect measures and computing estimates of effect","author":"Higgins","year":"2022"},{"issue":"9","key":"10.1016\/j.autrev.2022.103184_bb0065","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/sim.1761","article-title":"What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data","volume":"23","author":"Sweeting","year":"2004","journal-title":"Stat. Med."},{"issue":"4","key":"10.1016\/j.autrev.2022.103184_bb0070","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.autrev.2022.103184_bb0075","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.3","article-title":"Chapter 14: completing \u2018summary of findings\u2019 tables and grading the certainty of the evidence","author":"Sch\u00fcnemann","year":"2022"},{"issue":"4","key":"10.1016\/j.autrev.2022.103184_bb0080","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid. Based Ment. Health"},{"issue":"2","key":"10.1016\/j.autrev.2022.103184_bb0085","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/jrsm.11","article-title":"Outlier and influence diagnostics for meta-analysis","volume":"1","author":"Viechtbauer","year":"2010","journal-title":"Res. Synth. Methods"},{"issue":"3","key":"10.1016\/j.autrev.2022.103184_bb0090","first-page":"469","article-title":"Systemic lupus erythematosus: predictors of its occurrence among a cohort of patients with early undifferentiated connective tissue disease: multivariate analyses and identification of risk factors","volume":"23","author":"Calvo-Alen","year":"1996","journal-title":"J. Rheumatol."},{"issue":"3","key":"10.1016\/j.autrev.2022.103184_bb0095","first-page":"313","article-title":"Five-year follow-up of 665 Hungarian patients with undifferentiated connective tissue disease (UCTD)","volume":"21","author":"Bodolay","year":"2003","journal-title":"Clin. Exp. Rheumatol."},{"issue":"2","key":"10.1016\/j.autrev.2022.103184_bb0100","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1191\/096120300678828073","article-title":"Clinical outcome and predictors of disease evolution in patients with incomplete lupus erythematosus","volume":"9","author":"Vila","year":"2000","journal-title":"Lupus"},{"issue":"12","key":"10.1016\/j.autrev.2022.103184_bb0105","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1111\/ijcp.12466","article-title":"Development of SLE among \u201cpotential SLE\u201d patients seen in consultation: long-term follow-up","volume":"68","author":"Al Daabil","year":"2014","journal-title":"Int. J. Clin. Pract."},{"issue":"2","key":"10.1016\/j.autrev.2022.103184_bb0110","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/acr2.11219","article-title":"A Multianalyte assay panel with cell-bound complement activation products predicts transition of probable lupus to American college of rheumatology-classified lupus","volume":"3","author":"Ramsey-Goldman","year":"2021","journal-title":"ACR Open Rheumatol."},{"issue":"4","key":"10.1016\/j.autrev.2022.103184_bb0115","first-page":"475","article-title":"Latent lupus","volume":"16","author":"Ganczarczyk","year":"1989","journal-title":"J. Rheumatol."},{"issue":"2","key":"10.1016\/j.autrev.2022.103184_bb0120","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1191\/0961203304lu477oa","article-title":"Outcome of incomplete systemic lupus erythematosus after 10 years","volume":"13","author":"Hallengren","year":"2004","journal-title":"Lupus"},{"issue":"11","key":"10.1016\/j.autrev.2022.103184_bb0125","first-page":"2345","article-title":"Undifferentiated connective tissue disease: analysis of 83 patients with a minimum followup of 5 years","volume":"29","author":"Mosca","year":"2002","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.autrev.2022.103184_bb0130","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1136\/annrheumdis-2015-eular.4913","article-title":"UCTD and progression to SLE. Analysis of a wide monocentric cohort with a long follow-up","volume":"74","author":"Bortoluzzi","year":"2015","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.autrev.2022.103184_bb0135","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/03009749950155751","article-title":"The prognosis and outcome of patients referred to an outpatient clinic for rheumatic diseases characterized by the presence of antinuclear antibodies (ANA)","volume":"28","author":"Dijkstra","year":"1999","journal-title":"Scand. J. Rheumatol."},{"issue":"4","key":"10.1016\/j.autrev.2022.103184_bb0140","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s00296-011-2234-y","article-title":"Undifferentiated connective tissue disease in a rheumatology center in Cali, Colombia: clinical features of 94 patients followed for a year","volume":"33","author":"Guerrero","year":"2013","journal-title":"Rheumatol. Int."},{"issue":"3","key":"10.1016\/j.autrev.2022.103184_bb0145","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/00124743-199506000-00005","article-title":"The \u2018rule out lupus\u2019 rheumatology consultation: clinical outcomes and perspectives","volume":"1","author":"Wallace","year":"1995","journal-title":"J. Clin. Rheumatol."},{"issue":"4","key":"10.1016\/j.autrev.2022.103184_bb0150","first-page":"403","article-title":"Undifferentiated connective tissue disease with antibodies to Ro\/SSA: clinical features and follow-up of 148 patients","volume":"19","author":"Cavazzana","year":"2001","journal-title":"Clin. Exp. Rheumatol."},{"issue":"6","key":"10.1016\/j.autrev.2022.103184_bb0155","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1093\/rheumatology\/kez440","article-title":"Pregnancy and undifferentiated connective tissue disease: outcome and risk of flare in 100 pregnancies","volume":"59","author":"Zucchi","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.autrev.2022.103184_bb0165","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/art.41093","article-title":"Complement activation in patients with probable systemic lupus erythematosus and ability to predict progression to American college of rheumatology-classified systemic lupus erythematosus","volume":"72","author":"Ramsey-Goldman","year":"2020","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.autrev.2022.103184_bb0170","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0002-9343(96)00335-X","article-title":"The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases","volume":"101","author":"Merkel","year":"1996","journal-title":"Am. J. Med."},{"issue":"8","key":"10.1016\/j.autrev.2022.103184_bb0175","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1136\/ard.47.8.634","article-title":"Development of connective tissue disease in patients presenting with Raynaud\u2019s phenomenon: a six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting","volume":"47","author":"Kallenberg","year":"1988","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"10.1016\/j.autrev.2022.103184_bb0180","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1111\/1756-185X.13592","article-title":"Capillaroscopy changes are associated with disease progression in patients with early systemic sclerosis: a prospective study","volume":"22","author":"Zumstein Camargo","year":"2019","journal-title":"Int. J. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.autrev.2022.103184_bb0185","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.autrev.2017.05.013","article-title":"Very early and early systemic sclerosis in the Spanish scleroderma registry (RESCLE) cohort","volume":"16","author":"Trapiella-Martinez","year":"2017","journal-title":"Autoimmun. Rev."},{"issue":"12","key":"10.1016\/j.autrev.2022.103184_bb0190","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/art.41814","article-title":"Anticentromere antibody levels and isotypes and the development of systemic sclerosis","volume":"73","author":"van Leeuwen","year":"2021","journal-title":"Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.autrev.2022.103184_bb0195","first-page":"82","article-title":"From VEDOSS to established systemic sclerosis diagnosis according to ACR\/EULAR 2013 classification criteria: a French-Italian capillaroscopic survey","volume":"36 Suppl 113","author":"Vasile","year":"2018","journal-title":"Clin. Exp. Rheumatol."},{"issue":"9","key":"10.1016\/j.autrev.2022.103184_bb0200","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1093\/rheumatology\/keac006","article-title":"Predictors of progression to systemic sclerosis: analysis of Very Early Disease of Systemic Sclerosis (VEDOSS) in a large single cohort","volume":"61","author":"Siqueira","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.autrev.2022.103184_bb0205","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1046\/j.1365-4362.1999.00773.x","article-title":"Quantitative analysis of nailfold capillary abnormalities in patients with connective tissue diseases","volume":"38","author":"Ohtsuka","year":"1999","journal-title":"Int. J. Dermatol."},{"issue":"9","key":"10.1016\/j.autrev.2022.103184_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102358","article-title":"Undifferentiated connective tissue disease at risk of systemic sclerosis: a weighted score to identify patients who will evolve","volume":"18","author":"Riccardi","year":"2019","journal-title":"Autoimmun. Rev."},{"issue":"10","key":"10.1016\/j.autrev.2022.103184_bb0220","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1002\/acr.22304","article-title":"Early systemic sclerosis: analysis of the disease course in patients with marker autoantibody and\/or capillaroscopic positivity","volume":"66","author":"Valentini","year":"2014","journal-title":"Arthritis Care Res."},{"issue":"4","key":"10.1016\/j.autrev.2022.103184_bb0225","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/rheumatology\/keu381","article-title":"Role of class II human leucocyte antigens in the progression from early to definite systemic sclerosis","volume":"54","author":"Vigone","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.autrev.2022.103184_bb0235","first-page":"739","article-title":"Undifferentiated connective tissue disease: predictors of evolution into definite disease","volume":"35","author":"Garcia-Gonzalez","year":"2017","journal-title":"Clin. Exp. Rheumatol."},{"issue":"12","key":"10.1016\/j.autrev.2022.103184_bb0240","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1097\/00006231-200512000-00011","article-title":"High prevalence of oesophageal involvement in patients with undifferentiated connective tissue disease using radionuclide oesophageal transit scintigraphy","volume":"26","author":"Gaal","year":"2005","journal-title":"Nucl Med Commun."},{"issue":"1","key":"10.1016\/j.autrev.2022.103184_bb0245","first-page":"117","article-title":"Isotype switching and titer variation of anti-Ro\/SSA antibodies over time in 100 patients with undifferentiated connective tissue disease (UCTD)","volume":"26","author":"Ceribelli","year":"2008","journal-title":"Clin. Exp. Rheumatol."},{"issue":"2","key":"10.1016\/j.autrev.2022.103184_bb0250","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10067-005-1146-1","article-title":"Predictive value of nailfold capillaroscopy in patients with Raynaud\u2019s phenomenon","volume":"25","author":"Meli","year":"2006","journal-title":"Clin. Rheumatol."},{"issue":"5","key":"10.1016\/j.autrev.2022.103184_bb0255","doi-asserted-by":"crossref","first-page":"105381","DOI":"10.1016\/j.jbspin.2022.105381","article-title":"Persistent low complement levels and increased interferon gene expression are predictive for disease progression in patients with incomplete systemic lupus erythematosus","volume":"89","author":"Lambers","year":"2022","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.autrev.2022.103184_bb0260","article-title":"Causes of Raynaud\u2019s phenomenon and the predictive laboratory and capillaroscopy features for the evolution to a definite connective tissue disease","volume":"31","author":"Shenavandeh","year":"2021","journal-title":"Rheumatology"},{"issue":"8","key":"10.1016\/j.autrev.2022.103184_bb0265","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1093\/intimm\/dxn056","article-title":"Progressive divergent shifts in natural and induced T-regulatory cells signify the transition from undifferentiated to definitive connective tissue disease","volume":"20","author":"Szodoray","year":"2008","journal-title":"Int. Immunol."},{"issue":"6","key":"10.1016\/j.autrev.2022.103184_bb0270","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/0002-9343(82)90846-4","article-title":"A prospective study of Raynaud phenomenon and early connective tissue disease. A five-year report","volume":"72","author":"Harper","year":"1982","journal-title":"Am. J. Med."},{"issue":"3","key":"10.1016\/j.autrev.2022.103184_bb0275","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/0002-9343(87)90760-1","article-title":"How to classify Raynaud\u2019s phenomenon. long-term follow-up study of 73 cases","volume":"83","author":"Priollet","year":"1987","journal-title":"Am. J. Med."},{"key":"10.1016\/j.autrev.2022.103184_bb0285","first-page":"04","article-title":"A Multianalyte assay panel with cell-bound complement activation products predicts transition of probable lupus to American college of rheumatology-classified lupus","volume":"04","author":"Ramsey-Goldman","year":"2021","journal-title":"ACR Open Rheumatol."},{"issue":"12","key":"10.1016\/j.autrev.2022.103184_bb0290","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.humimm.2013.08.003","article-title":"Altered Th17 cells and Th17\/regulatory T-cell ratios indicate the subsequent conversion from undifferentiated connective tissue disease to definitive systemic autoimmune disorders","volume":"74","author":"Szodoray","year":"2013","journal-title":"Hum. Immunol."},{"issue":"6","key":"10.1016\/j.autrev.2022.103184_bb0295","first-page":"1093","article-title":"Diagnostic and predictive value of the lupus band test in undifferentiated connective tissue disease. A followup study","volume":"12","author":"Goldstein","year":"1985","journal-title":"J. Rheumatol."},{"issue":"6","key":"10.1016\/j.autrev.2022.103184_bb0300","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1097\/JIM.0000000000000094","article-title":"Autoantibodies to c-reactive protein in incomplete lupus and systemic lupus erythematosus","volume":"62","author":"Jung","year":"2014","journal-title":"J. Investig. Med."},{"issue":"2","key":"10.1016\/j.autrev.2022.103184_bb0305","doi-asserted-by":"crossref","DOI":"10.3390\/antib10020012","article-title":"New autoantibody specificities in systemic sclerosis and very early systemic sclerosis","volume":"10","author":"Lande","year":"2021","journal-title":"Antibodies"},{"issue":"12","key":"10.1016\/j.autrev.2022.103184_bb0310","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1136\/annrheumdis-2018-213257","article-title":"Association of circulating CXCL10 and CXCL11 with systemic sclerosis","volume":"77","author":"Crescioli","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"12","key":"10.1016\/j.autrev.2022.103184_bb0315","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1002\/art.40243","article-title":"Earliest phase of systemic sclerosis typified by increased levels of inflammatory proteins in the serum","volume":"69","author":"Cossu","year":"2017","journal-title":"Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.autrev.2022.103184_bb0320","doi-asserted-by":"crossref","DOI":"10.1186\/ar4019","article-title":"Early systemic sclerosis: short-term disease evolution and factors predicting the development of new manifestations of organ involvement","volume":"14","author":"Valentini","year":"2012","journal-title":"Arthritis Res. Ther."},{"issue":"3","key":"10.1016\/j.autrev.2022.103184_bb0325","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s10238-016-0437-y","article-title":"CXCL4 in undifferentiated connective tissue disease at risk for systemic sclerosis (SSc) (previously referred to as very early SSc)","volume":"17","author":"Valentini","year":"2017","journal-title":"Clin. Exp. Med."},{"issue":"1","key":"10.1016\/j.autrev.2022.103184_bb0330","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13075-017-1243-y","article-title":"Presence of an interferon signature in individuals who are anti-nuclear antibody positive lacking a systemic autoimmune rheumatic disease diagnosis","volume":"19","author":"Wither","year":"2017","journal-title":"Arthritis. Res. Ther."},{"issue":"1","key":"10.1016\/j.autrev.2022.103184_bb0335","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-019-2013-9","article-title":"Fatigue severity in anti-nuclear antibody-positive individuals does not correlate with pro-inflammatory cytokine levels or predict imminent progression to symptomatic disease","volume":"21","author":"Hafiz","year":"2019","journal-title":"Arthritis Res. Ther."},{"issue":"3","key":"10.1016\/j.autrev.2022.103184_bb0340","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1093\/rheumatology\/keab501","article-title":"Serological abnormalities that predict progression to systemic autoimmune rheumatic diseases in antinuclear antibody-positive individuals","volume":"61","author":"Munoz-Grajales","year":"2022","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.autrev.2022.103184_bb0350","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/rheumatology\/40.1.89","article-title":"Incomplete lupus erythematosus: results of a multicentre study under the supervision of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCISIT)","volume":"40","author":"Swaak","year":"2001","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.autrev.2022.103184_bb0355","first-page":"585","article-title":"Five-year follow-up of 165 Italian patients with undifferentiated connective tissue diseases","volume":"17","author":"Danieli","year":"1999","journal-title":"Clin. Exp. Rheumatol."},{"issue":"8","key":"10.1016\/j.autrev.2022.103184_bb0360","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s10067-009-1175-2","article-title":"Undifferentiated connective tissue disease: a seven-center cross-sectional study of 184 patients","volume":"28","author":"Vaz","year":"2009","journal-title":"Clin. Rheumatol."},{"issue":"6","key":"10.1016\/j.autrev.2022.103184_bb0365","first-page":"831","article-title":"Systemic lupus erythematosus. Differences between patients who do, and who do not, fulfill classification criteria at the time of diagnosis","volume":"7","author":"Lom-Orta","year":"1980","journal-title":"J. Rheumatol."},{"issue":"3","key":"10.1016\/j.autrev.2022.103184_bb0375","first-page":"471","article-title":"Analysis of the evolution of UCTD to defined CTD after a long term follow-up","volume":"31","author":"Mosca","year":"2013","journal-title":"Clin. Exp. Rheumatol."},{"issue":"4","key":"10.1016\/j.autrev.2022.103184_bb0380","first-page":"816","article-title":"Early undifferentiated connective tissue disease (CTD). VI. An inception cohort after 10 years: disease remissions and changes in diagnoses in well established and undifferentiated CTD","volume":"26","author":"Williams","year":"1999","journal-title":"J. Rheumatol."},{"issue":"7","key":"10.1016\/j.autrev.2022.103184_bb0385","first-page":"1573","article-title":"Criteria for the classification of early systemic sclerosis","volume":"28","author":"LeRoy","year":"2001","journal-title":"J. Rheumatol."},{"issue":"9","key":"10.1016\/j.autrev.2022.103184_bb0390","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1136\/ard.2008.106302","article-title":"The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy","volume":"68","author":"Matucci-Cerinic","year":"2009","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.autrev.2022.103184_bb0395","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/ard.2006.062901","article-title":"Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database","volume":"66","author":"Walker","year":"2007","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.autrev.2022.103184_bb0405","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/rheumatology\/kew212","article-title":"Vitamin D treatment for connective tissue diseases: hope beyond the hype?","volume":"56","author":"Reynolds","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.autrev.2022.103184_bb0410","doi-asserted-by":"crossref","first-page":"R123","DOI":"10.1186\/ar2533","article-title":"Vitamin D deficiency in undifferentiated connective tissue disease","volume":"10","author":"Zold","year":"2008","journal-title":"Arthritis. Res. Ther."},{"issue":"6","key":"10.1016\/j.autrev.2022.103184_bb0415","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/0961203307078579","article-title":"Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus","volume":"16","author":"James","year":"2007","journal-title":"Lupus."},{"issue":"1","key":"10.1016\/j.autrev.2022.103184_bb0420","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1186\/s13063-018-3076-7","article-title":"Study of anti-malarials in incomplete lupus erythematosus (SMILE): study protocol for a randomized controlled trial","volume":"19","author":"Olsen","year":"2018","journal-title":"Trials"},{"key":"10.1016\/j.autrev.2022.103184_bb0425","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.869172","article-title":"Precursors to systemic sclerosis and systemic lupus erythematosus: from undifferentiated connective tissue disease to the development of identifiable connective tissue diseases","volume":"13","author":"Martin Calderon","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.autrev.2022.103184_bb0430","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41584-021-00710-2","article-title":"Differentiating between UCTD and early-stage SLE: from definitions to clinical approach","volume":"18","author":"Sciascia","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"issue":"3","key":"10.1016\/j.autrev.2022.103184_bb0435","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/art.40004","article-title":"Discerning risk of disease transition in relatives of systemic lupus erythematosus patients utilizing soluble mediators and clinical features","volume":"69","author":"Munroe","year":"2017","journal-title":"Arthritis Rheum."},{"issue":"10","key":"10.1016\/j.autrev.2022.103184_bb0440","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1136\/annrheumdis-2018-213386","article-title":"Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status","volume":"77","author":"Md Yusof","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.autrev.2022.103184_bb0445","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/sj.gene.6364408","article-title":"High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus","volume":"8","author":"Niewold","year":"2007","journal-title":"Genes Immun."},{"issue":"12","key":"10.1016\/j.autrev.2022.103184_bib446","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1177\/0961203311409610","article-title":"Pregnancy in patients with undifferentiated connective tissue disease: A prospective case-control study","volume":"20","author":"Castellino","year":"2011","journal-title":"Lupus"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997222001549?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997222001549?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:11:57Z","timestamp":1778821917000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997222001549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":83,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1568997222001549"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2022.103184","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predicting progression from undifferentiated connective tissue disease to definite connective tissue disease: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2022.103184","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103184"}}